Robert Yarchoan, M.D., and Thomas S. Uldrick, M.D.
From the HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Address reprint requests to Dr. Yarchoan at the National Cancer Institute, 10 Center Dr., Rm. 6N106, MSC1868, Bethesda, MD 20892, or at firstname.lastname@example.org.
1. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men — New York City and California. MMWR Morb Mortal Wkly Rep 1981;30:305-308.
2. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
3. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753-762.
4. Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017;4(11):e495-e504.
5. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002;94:1204-1210.
6. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med 2015;163:507-518.
7. Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 2015;107:107-107.
8. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 2014;28:1181-1191.
9. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335:123-128.
10. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266:1865-1869.
11. Martínez-Maza O, Breen EC. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol 2002;14:528-532.
12. de Martel C, Shiels MS, Franceschi S, et al. Cancers attributable to infections among adults with HIV in the United States. AIDS 2015;29:2173-2181.
13. Shebl FM, Engels EA, Goedert JJ, Chaturvedi AK. Pulmonary infections and risk of lung cancer among persons with AIDS. J Acquir Immune Defic Syndr 2010;55:375-379.
14. Gao S-J, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med 1996;2:925-928.
15. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007;357:1352-1353.
16. Royse KE, El Chaer F, Amirian ES, et al. Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. PLoS One 2017;12(8):e0182750-e0182750.
17. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739-1744.
18. Montaner S, Sodhi A, Ramsdell AK, et al. The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi’s sarcoma. Cancer Res 2006;66:168-174.
19. Haque M, Davis DA, Wang V, Widmer I, Yarchoan R. Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia. J Virol 2003;77:6761-6768.
20. Rabkin CS, Bedi G, Musaba E, et al. AIDS-related Kaposi’s sarcoma is a clonal neoplasm. Clin Cancer Res 1995;1:257-260.
21. Duprez R, Lacoste V, Brière J, et al. Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J Natl Cancer Inst 2007;99:1086-1094.
22. Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989;7:1201-1207.
23. Krown SE, Testa MA, Huang J. AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. J Clin Oncol 1997;15:3085-3092.
24. Martin-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi’s sarcoma. AIDS 2004;18:1737-1740.
25. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS 2009;23:1701-1706.
26. Letang E, Lewis JJ, Bower M, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS 2013;27:1603-1613.
27. Gill PS, Loureiro C, Bernstein-Singer M, Rarick MU, Sattler F, Levine AM. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;110:937-940.
28. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-2451.
29. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010;116:3969-3977.
30. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 1998;16:1112-1121.
31. Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi’s sarcoma in people with and without HIV I\infection: a phase I/II study. J Clin Oncol 2016;34:4125-4131.
32. Shimabukuro K, Moore PC, Bui J, et al. Lenalidomide is safe and effective in AIDS-associated Kaposi sarcoma. Presented at the 16th International Conference on Malignancies in HIV/AIDS, Bethesda, MD, October 23–24, 2017.
33. Chalya PL, Mbunda F, Rambau PF, et al. Kaposi’s sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania. BMC Res Notes 2015;8:440-440.
34. Chinula L, Moses A, Gopal S. HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities. Curr Opin HIV AIDS 2017;12:89-95.
35. AIDS–Kaposi’s sarcoma study changed due to drug underperformance; oral etoposide plus antiretroviral therapy study arm Discontinued. Press release from the National Institutes of Health, March 18, 2016 (https://www.niaid.nih.gov/news-events/aids-kaposi’s-sarcoma-study-changed-due-drug-underperformance).
36. Maskew M, Fox MP, van Cutsem G, et al. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study. PLoS One 2013;8(6):e64392-e64392.
37. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma–associated herpesvirus-like DNA sequences in AIDS-related body-cavity–based lymphomas. N Engl J Med 1995;332:1186-1191.
38. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995;86:1276-1280.
39. Polizzotto MN, Uldrick TS, Wyvill KM, et al. Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV inflammatory cytokine syndrome (KICS). Clin Infect Dis 2016;62:730-738.
40. Guillet S, Gérard L, Meignin V, et al. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol 2016;91:233-237.
41. Sanchez-Martin D, Uldrick TS, Kwak H, et al. Evidence for a mesothelial origin of body cavity effusion lymphomas. J Natl Cancer Inst 2017;109:109-109.
42. Uldrick TS, Polizzotto MN, Filie A, et al. Clinical, immunologic, and virologic findings in Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas suggest KSHV-associated inflammatory syndromes contribute to symptoms and disease pathogenesis. Presented at the 54th American Society of Hematology Annual Meeting, Atlanta, December 8–11, 2012.
43. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996;10:61-67.
44. Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol 2004;43:698-704.
45. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood 2001;97:2526-2527.
46. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000;96:2069-2073.
47. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2013;122:4189-4198.
48. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007;25:3350-3356.
49. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood 2010;116:4415-4421.
50. Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood 2014;124:3544-3552.
51. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011;117:6977-6986.
52. Uldrick TS, Wang V, O’Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease. Clin Infect Dis 2010;51:350-358.
53. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-1420.
54. Uldrick TS, Little RF. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Blood 2015;125:1226-1235.
55. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338:969-973.
56. Valera A, Balagué O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010;34:1686-1694.
57. Hwang JP, Granwehr BP, Torres HA, et al. HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract 2015;11:384-390.
58. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005;105:496-502.
59. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999;17:554-560.
60. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010;115:3017-3024.
61. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med 2013;369:1915-1925.
62. Coutinho R, Pria AD, Gandhi S, et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS 2014;28:689-697.
63. Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 2012;30:4111-4116.
64. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood 2013;122:3251-3262.
65. Alvarnas JC, Le Rademacher J, Wang Y, et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood 2016;128:1050-1058.
66. Uldrick TS, Pipkin S, Scheer S, Hessol NA. Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS 2014;28:397-405.
67. Noy A, Lensing SY, Moore PC, et al. Plasmablastic lymphoma is treatable in the HAART era: a 10 year retrospective by the AIDS Malignancy Consortium. Leuk Lymphoma 2016;57:1731-1734.
68. Goncalves PH, Uldrick TS, Aleman K, et al. Radiation-sparing treatment of acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma with highly active antiretroviral therapy (HAART), rituximab, and high dose methotrexate with leucovorin rescue. Presented at the 15th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies, Bethesda, MD, October 26–27, 2015.
69. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011;12:905-912.
70. Silverberg MJ, Leyden W, Warton EM, Quesenberry CP Jr, Engels EA, Asgari MM. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013;105:350-360.
71. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol 2008;26:1027-1032.
72. Beaver JA, Ison G, Pazdur R. Reevaluating eligibility criteria — balancing patient protection and participation in oncology trials. N Engl J Med 2017;376:1504-1505.
73. Uldrick TS, Ison G, Rudek MA, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group. J Clin Oncol 2017;35:3774-3780.
74. Picard A, Badoual C, Hourseau M, et al. Human papilloma virus prevalence in HIV patients with head and neck squamous cell carcinoma. AIDS 2016;30:1257-1266.
75. DʼSouza G, Carey TE, William WN Jr, et al. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 2014;65:603-610.
76. Williams AB, Darragh TM, Vranizan K, Ochia C, Moss AR, Palefsky JM. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994;83:205-211.
77. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010;201:681-690.
78. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012;13:487-500.
79. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: human papillomavirus disease. AIDSinfo 2016 (https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/343/hpv).
80. Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010;102:1557-1567.
81. Goncalves PH, Montezuma-Rusca JM, Yarchoan R, Uldrick TS. Cancer prevention in HIV-infected populations. Semin Oncol 2016;43:173-188.
82. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-1173.
83. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202:1246-1253.
84. Casper C, Krantz E, Selke S, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis 2007;195:30-36.
85. Butler LM, Dorsey G, Hladik W, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis 2009;200:430-438.
86. Phillips AM, Jones AG, Osmond DH, Pollack LM, Catania JA, Martin JN. Awareness of Kaposi’s sarcoma-associated herpesvirus among men who have sex with men. Sex Transm Dis 2008;35:1011-1014.
87. Osmond DH, Buchbinder S, Cheng A, et al. Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA 2002;287:221-225.
88. Hulbert A, Hooker CM, Keruly JC, et al. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol 2014;9:752-759.
89. NCCN clinical practice guidelines in oncology: B-cell lymphomas, version 4. National Comprehensive Cancer Network, 2017 (https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf).